Vanguard Capital Management
CAMP icon

Vanguard Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Vanguard Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7M Sell
1,533,489
-1,279
-0.1% -$5.51K ﹤0.01% 3009
2026
Q1 		$6.77M Buy
+1,534,768
New +$7.29M ﹤0.01% 2933

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard Capital Management's CAMP Position: Q2 2026 in Review

Vanguard Capital Management reduced its CAMP4 Therapeutics (CAMP) stake by 0.08% in Q2 2026, selling an estimated $5.51K and leaving 1,533,489 shares worth $6.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

Vanguard Capital Management first reported a position in CAMP in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.77M in Q1 2026. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Vanguard Capital Management held 1,533,489 shares of CAMP4 Therapeutics worth $6.7M as of Q2 2026.
  • Vanguard Capital Management sold 1,279 CAMP4 Therapeutics shares in Q2 2026, an estimated $5.51K.
  • CAMP4 Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3009 holding.
  • Vanguard Capital Management first reported a position in CAMP4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's CAMP4 Therapeutics position peaked at $6.77M in Q1 2026.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.